Financial Analysis: NovoCure (NASDAQ:NVCR) versus Heart Test Laboratories (NASDAQ:HSCSW)

Heart Test Laboratories (NASDAQ:HSCSW) and NovoCure (NASDAQ:NVCR) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.

Profitability

This table compares Heart Test Laboratories and NovoCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Heart Test Laboratories	N/A	N/A	N/A
NovoCure	-21.25%	-44.00%	-15.85%

Insider and Institutional Ownership

84.6% of NovoCure shares are held by institutional investors. 6.6% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Heart Test Laboratories and NovoCure”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heart Test Laboratories	$4,319.00	N/A	N/A	N/A	N/A
NovoCure	$699.19 million	2.96	-$136.23 million	($1.30)	-13.67

Heart Test Laboratories has higher earnings, but lower revenue than NovoCure.

Analyst Ratings

This is a breakdown of current ratings for Heart Test Laboratories and NovoCure, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heart Test Laboratories	0	0	0	0	0.00
NovoCure	1	4	2	0	2.14

NovoCure has a consensus price target of $21.20, indicating a potential upside of 19.30%. Given NovoCure’s stronger consensus rating and higher probable upside, analysts clearly believe NovoCure is more favorable than Heart Test Laboratories.

Summary

NovoCure beats Heart Test Laboratories on 6 of the 9 factors compared between the two stocks.

About Heart Test Laboratories

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.